----

**EXHIBIT      10.33**

**THIRD      AMENDMENT**

**TO      THE**

**MANUFACTURING      AND SUPPLY AGREEMENT OF DECEMBER 7 2003**

**3**
**rd**

**Amendment**
**LB**
**Lonza      Inc**
**Lonza**
**Genentech**

**BACKGROUND**

**1**
**st**

**      Amendment**
**Agreement**
**2**
**nd**

**      Amendment**

**[*]**
**[*]**

| **1****.** | **Condition                Precedent.**This                3rd                Amendment shall only become effective upon the closing of the purchase                and                sale of the issued and outstanding units of Genentech España S.L.,                pursuant to the terms of the Sale                Agreement (the                “**3****rd****Amendment Effective Date**”).                As of the signing of this 3rd                Amendment, the expected closing date of the Sale Agreement is 08                December                06. As used herein, the “**Sale                Agreement**”                means that                certain Stock Purchase Agreement by                and among Lonza                Europe B.V.,                a Dutch company incorporated in the Netherlands, having its principal                place of business at Breda, Netherlands and Genentech,                of even date herewith, pursuant to which Genentech has agreed to                sell the                “Shares” (as defined in the Sale Agreement) to Lonza, and Lonza has agreed                to purchase the Shares from Genentech, as the same may be amended                from                time to time. |
|------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| **2.** | **Rescheduling                of Campaigns**.                Notwithstanding                the Campaign, Campaign Minimum and Campaign Minimum Run schedule                listed on                Exhibit A of the Agreement (including any amendments thereof in the                1st                Amendment and/or 2nd                Amendment): |
|--------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**(a)**
**[*]      **
**[*]**
**[*]**
**[*]**
**[*]**

----

**(b)**
**[*]**

**Campaign        **
**Campaign      Minimum Runs**

**[*]**
**[*]**

**[*]**
**[*]**

**[*]**
**[*]**

| **3.** | **Competitive                Products**.                A new Section 5.7.7 is hereby added to the Agreement as                follows: |
|--------|-----------------------------------------------------------------------------------------------------------------------------------------|

|   | 5.7.7 | Competitive                Products.                Notwithstanding the non-compete provisions of Section 5.7.6, if                any existing or new capacity becomes available at the Lonza Facility                at                any time **[*]**,                Lonza shall have the right to use such capacity to manufacture,                either for commercial supply or clinical supply, an Existing Lonza                Customer Product (including without limitation those Existing Lonza                Customer Product that are Competing Products). Each                Party agrees that the provisions of this Section 5.7.7 shall be binding                upon the licensees, successors and/or assignees of a Party. As                used herein this Section 5.7.7: |
|--------|-------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**[*]**
**Singapore      Facility**
**“Competing      Product**

**Existing      Lonza Customer Product**
**[*]**

| **4**. | **Term**.                Section 20.1 of the Agreement is amended in its entirety to read                as                follows: |
|--------|-------------------------------------------------------------------------------------------------------------------------------------|

|   | 20.1 | Term.                Unless sooner terminated pursuant to the terms of this Agreement,                the term                of this Agreement (the "Term") shall commence on the Effective Date                and                shall continue until December 31,                2008. |
|--------|------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| **5.** | **Capacity                at the Lonza Facility in the [*]**.                A new Section 5.10 is hereby added to the Agreement as                follows: |
|--------|-------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 5.10 | Capacity                at                the Lonza Facility in **[*]**.                Lonza hereby agrees to provide to Genentech notice of any capacity                (new or                existing) at the Lonza Facility (and not already committed under                written                agreement with a Third Party as of the date of such notice), for                so long                as such capacity is available for production during **[*]**.                This                Section 5.10 shall survive the termination or expiration of this                Agreement. |
|--------|------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 5.10.1 | Forecast                Notice.                Commencing on **[*]**,                and continuing every six (6) months thereafter until **[*]**,                Lonza shall provide Genentech with a forecast of available capacity                (including without limitation that portion of capacity, if any, under                discussion by Lonza with a Third Party) at the Lonza Facility in                **[*]**.                Lonza shall offer such capacity to Genentech **[*]**.                Genentech shall have **[*]**                (as may be extended by mutual agreement) following its receipt of                each                such forecast to provide written notification to Lonza regarding                its                decision **[*]**with                respect to any of such capacity. |
|--------|--------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 5.10.2 | Exercise.                If written notice is given by Genentech to Lonza within such **[*]**                period that Genentech may desire to obtain some or all of such capacity,                Lonza shall provide Genentech with all information reasonably useful                for                Genentech to make a decision regarding such capacity. Following                Genentech’s receipt of all such information, **[*]**. |
|--------|--------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 5.10.3 | Failure                to Exercise; Election to Not Exercise.                If written notice is given that Genentech does not want to accept                some or                all of such capacity, or written notice is not given by Genentech                within                **[*]**                (as may be extended by mutual agreement), Genentech will have waived                its                right to **[*]**                capacity (or, as applicable, that portion thereof that it specifies                in                such written notice that it does not want **[*]**)                unless and until Lonza notifies Genentech in a subsequent forecast                that                such capacity is available. |
|--------|--------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 5.10.4 | Additional                Rights/Obligations. |
|--------|--------|-----------------------------------------------|

**[*]**

----

**[*]**
**[*]**

| **6.** | **Milestone                Payment for Calendar Year 2006**.                Section 6.4.3(d)(ii) is amended in entirety as                follows: |
|--------|----------------------------------------------------------------------------------------------------------------------------------------------------|

**[*]**
**[*]      **
**[*]**
**[*]**
**[*]**
**[*]**
**[*]**
**[*]**
**[*]**

| **7.** | All                terms and conditions of the Agreement not modified by this 3rd                Amendment shall continue in full force and effect in accordance with                their                terms. All capitalized terms not otherwise defined herein shall have                the                same definition as in the                Agreement. |
|--------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| GENENTECH,                INC.       |                                                                       |
|--------------------------------------|----------------------------------------------------------------------------|
|                                 |                                                                       |   |
| By:                                  | /s/  MARKUS                GEMUEND                               |   |
|                                 |                                                                       |   |
| Name:                                | Markus                Gemuend                                              |   |
|                                 |                                                                       |   |
| Title:                               | Vice                President, Manufacturing                Collaborations |   |
|                                 |                                                                       |   |
|                                 |                                                                       |   |
| LONZA                BIOLOGICS, INC. |                                                                       |
|                                 |                                                                       |   |
| By:                                  | /s/  STEPHAN                KUTZER                               |   |
|                                 |                                                                       |   |
| Name:                                | Stephan                Kutzer                                              |   |
|                                 |                                                                       |   |
| Title:                               | Chief                Operating Officer                                     |   |
|                                 |                                                                       |   |
|                                 |                                                                       |   |
| LONZA                BIOLOGICS, PLC  |                                                                       |
|                                 |                                                                       |   |
| By:                                  | /s/  STEPHAN                KUTZER                               |   |
|                                 |                                                                       |   |
| Name:                                | Stephan                Kutzer                                              |   |
|                                 |                                                                       |   |
| Title:                               | Chief                Operating Officer                                     |   |

----

----